The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Manturova N.E.

Kafedra plasticheskoĭ i ésteticheskoĭ khirurgii, kosmetologii i kletochnykh tekhnologiĭ GBOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdravsotsrazvitiia Rossii

Abdulaev R.T.

Institute of Plastic Surgery and Cosmetology, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Ustyugov A.Yu.

JSC 'Plastic Surgery and Cosmetology Institute', Moscow, Russia;
Russian State Research Medical University n.a. N.I. Pirogov, Moscow, Russia

Breast implant-associated anaplastic large cell lymphoma

Authors:

Manturova N.E., Abdulaev R.T., Ustyugov A.Yu.

More about the authors

Journal: Plastic Surgery and Aesthetic Medicine. 2020;(2): 5‑14

DOI: 10.17116/plast.hirurgia20200215

Read: 11093 times

Download PDF (RU)
Contact the author
Table of contents

BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA
BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA

To cite this article:

Manturova NE, Abdulaev RT, Ustyugov AYu. Breast implant-associated anaplastic large cell lymphoma. Plastic Surgery and Aesthetic Medicine. 2020;(2):5‑14. (In Russ.)
https://doi.org/10.17116/plast.hirurgia20200215

Подписка 2026 Пластическая хирургия и эстетическая медицина (Plastic Surgery and Aesthetic Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell ALK-/CD30+ lymphoma occurring in 7—10 years after implantation of breast prostheses (textured forms as a rule). BIA-ALCL incidence ranges from 1:1000 to 1:10 000. To date, over 500 cases of BIA-ALCL are confirmed among 35 million implantations in the world. BIA-ALCL requires only surgical treatment after early diagnosis. Adherence to the modern guidelines on the diagnosis and treatment of this disease ensures complete recovery in most patients with BIA-ALCL. Nevertheless, adjuvant therapy including radio- and chemotherapy with brentuximab vedotin is required for tumor stage II—IV. Increased awareness of physicians and patients about the risks of BIA-ALCL, as well as targeted collection of epidemiological data can result an increased number of newly detected cases in the Russian Federation.

Keywords:

breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
anaplastic large cell lymphomas (ALCL)
Food and Drug Administration
anaplastic lymphoma kinase

Authors:

Manturova N.E.

Kafedra plasticheskoĭ i ésteticheskoĭ khirurgii, kosmetologii i kletochnykh tekhnologiĭ GBOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdravsotsrazvitiia Rossii

Abdulaev R.T.

Institute of Plastic Surgery and Cosmetology, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Ustyugov A.Yu.

JSC 'Plastic Surgery and Cosmetology Institute', Moscow, Russia;
Russian State Research Medical University n.a. N.I. Pirogov, Moscow, Russia

Close metadata

References:

  1. Talwalkar SS, Miranda RN, Valbuena JR, Routbort MJ, Martin AW, Medeiros LJ. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008;32(9):1299-1309.
  2. Validire P, Capovilla M, Asselain B, Kirova Y, Goudefroye R, Plancher C, Fourquet A, Zanni M, Gaulard P, Vincent-Salomon A, Decaudin D. Primary breast non-Hodgkin’s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol. 2009; 84(3):133-139.
  3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127:2375-2390.
  4. Keech JA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997;100:554-555.
  5. FDA. Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. USA, Maryland: FDA. Publishing date June 24, 2019. https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma
  6. FDA. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). USA, Maryland: FDALast accessed on 2 July 2017. www.fda.gov/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/breastimplants/ucm239995.htm
  7. FDA. Medical device reports of breast implant-associated anaplastic large cell lymphoma. USA, Maryland: FDA. Last accessed on 8 April 2018. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm481899.htm
  8. de Boer M, van Leeuwen FE, Hauptmann M, Overbeek LIH, de Boer JP, Hijmering NJ, Sernee A, Klazen CAH, Lobbes MBI, van der Hulst RRWJ, Rakhorst HA, de Jong D. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4: 335-341.
  9. FDA. Anaplastic large cell lymphoma (ALCL) in women with breast implants: preliminary FDA findings and analyses. In: Services DoHaH (ed). Washington, DC: US Food and Drug Administration; 2013..
  10. de Boer M, van der Sluis WB, de Boer JP, Overbeek LIH, van Leeuwen FE, Rakhorst HA, van der Hulst RRWJ, Hijmering NJ, Bouman MB, de Jong D. Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a Transgender Woman. Aesthet Surg J. 2017;37(8):NP83-NP87.
  11. Ali N, Sindhu K, Bakst RL. A Rare Case of a Transgender Female With Breast Implant-Associated Anaplastic Large Cell Lymphoma Treated With Radiotherapy and a Review of the Literature. J Investig Med High Impact Case Rep. 2019;7:2324709619842192.
  12. Doren EL, Miranda RN, Selber JC, et al. US. epidemiology of breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg. 2017; 139:1042-1050.
  13. Loch-Wilkinson A, Beath KJ, Knight RJW, Wessels WLF, Magnusson M, Papadopoulos T, Connell T, Lofts J, Locke M, Hopper I, Cooter R, Vickery K, Joshi PA, Prince HM, Deva AK. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140:645-654.
  14. Clemens MW, Miranda RN. Coming of age: breast implant-associated anaplastic large cell lymphoma after 18 years of investigation. Clin Plast Surg. 2015;42:605-613.
  15. Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein AL. Anaplastic large cell lymphoma occurring in women with breast implants Analysis of 173 cases. Plast Reconstr Surg. 2015;135:695-705.
  16. Lipworth L, Tarone RE, McLaughlin JK. Breast implants and lymphoma risk: a review of the epidemiologic evidence through 2008. Plast Reconstr Surg. 2009;123:790-793.
  17. de Jong D, Vasel WL, de Boer JP, Verhave G, Barbé E, Casparie MK, van Leeuwen FE. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300:2030-2035. [PubMed] [Google Scholar].
  18. Breast implants and anaplastic large cell lymphoma. TGA’s review of textured breast implants and preliminary outcomes. Update 11 July 2019. Accessed October 23, 2019. https://www.tga.gov.au/alert/breast-implants-and-anaplastic-large-cell-lymphoma
  19. Magnusson M, Beath K, Cooter R, Locke M, Prince HM, Elder E, Deva AK. The Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants. Plast Reconstr Surg. 2019;143(5):1285-1292.
  20. Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30-40.
  21. McGuire P, Reisman NR, Murphy DK. Risk Factor Analysis for Capsular Contracture, Malposition, and Late Seroma in Subjects Receiving Natrelle 410 Form-Stable Silicone Breast Implants. Plast Reconstr Surg. 2017;139(1): 1-9.
  22. FDA Webcast. General and Plastic Surgery Devices Panel Meeting. March 25—26, 2019. Accessed October 23, 2019. Day 1. https://fda.yorkcast.com/webcast/Play/a6baa43b37004ecab288779ac3a263bd1d
  23. Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2018;14:586-599.
  24. Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastical large cell lymphoma. Aesthet Surg J. 2017;37:285-289.
  25. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160-168.
  26. Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(Suppl. 1):3-13.
  27. Kim B, Predmore ZS, Mattke S, et al. Breast-implant-associated anaplastic large cell lymphoma: updated results from a structured expert consultation process. Plast Reconstr Surg Glob Open. 2015;3.
  28. NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines Version 2.2019 T-cell Lymphomas. Accessed October 23, 2019. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf
  29. Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct-pathological entity. Haematologica. 2010;95.
  30. Kim B, Roth C, Chung KC, Young VL, van Busum K, Schnyer C, Mattke S. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg. 2011;127.
  31. George EV, Pharm J, Houston C, et al. Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis. Int J Clin Exp Pathol. 2013;6.
  32. Bizjak M, Selmi C, Praprotnik S, Bruck O, Perricone C, Ehrenfeld M, Shoenfeld Y. Silicone implants and lymphoma: the role of inflammation. J Autoimmun. 2015;65:64-73.
  33. Orciani M, Sorgentoni G, Torresetti M, Di Primio R, Di Benedetto G. MSCs and inflammation: new insights into the potential association between ALCL and breast implants. Breast Cancer Res Treat. 2016;156:65-72.
  34. Adlard J, Burton C, Turton P. Increasing Evidence for the Association of Breast Implant-Associated Anaplastic Large Cell Lymphoma and Li Fraumeni Syndrome. Case Rep Genet. 2019;2019:5647940.
  35. Srinivasa DR, Miranda RN, Kaura A, Francis AM, Campanale A, Boldrini R, Alexander J, Deva AK, Gravina PR, Medeiros LJ, Nast K, Butler CE, Clemens MW. Global Adverse Event Reports of Breast Implant-Associated ALCL: an international review of 40 government authority databases. Plast Reconstr Surg. 2017;139:1029-1039.
  36. Adams WP Jr. Discussion: Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg. 2016; 137:1670-1672.
  37. Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, Brody G, Clemens M, Cheah CY, Lade S, Joshi PA, Prince HM, Deva AK. Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg. 2016;137:1659-1669.
  38. Adams WP Jr, Culbertson EJ, Deva AK, R Magnusson M, Layt C, Jewell ML, Mallucci P, Hedén P. Macrotextured Breast Implants with Defined Steps to Minimize Bacterial Contamination around the Device: Experience in 42,000 Implants. Plast Reconstr Surg. 2017;140(3):427-431.
  39. Barnsley GP, Sigurdson LJ, Barnsley SE. Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2006;117:2182-2190.
  40. Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol. 2016;6(9):160232.
  41. Du MQ. MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism. Best Pract Res Clin Haematol. 2017;30(1-2):13-23.
  42. Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesthetic Plast Surg. 2018;42(3):672-678.
  43. Fleming D, Stone J, Tansley P. Reply to the Editor Regarding: Magnusson MR, Deva AK Letter to the Editor 2018 May 2 in Relation to: Fleming D, Stone J, Tansley P. Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Implications for Research, Diagnosis and Clinical Management. Aesthetic Plast Surg. 2018;42(4): 1167-1169.
  44. Shauly O, Gould DJ, Siddiqi I, Patel KM, Carey J. The First Reported Case of Gluteal Implant-Associated Anaplastic Large Cell Lymphoma (ALCL). Aesthet Surg J. 2019;39(7):253-258.
  45. Palraj B, Paturi A, Stone RG, Alvarez H, Sebenik M, Perez MT, Bush LM. Soft tissue anaplastic large T-cell lymphoma associated with a metallic orthopedic implant: case report and review of current literature. J Foot Ankle Surg. 2010;49.
  46. Coleman MP. Cancer risk from orthopedic prostheses. Ann Clin Lab Sci. 1996;26:139-146.
  47. Yoon HJ, Choe JY, Jeon YK. Mucosal CD30-positive T-cell lymphoproliferative disorder arising in the oral cavity following dental implants: report of the first case. Int J Surg Pathol. 2015;23:656-661.
  48. Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF, Li J, Deva A, Johnstone RW, Khot A, Prince HM, Westerman D. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica. 2016;101(9):387-390.
  49. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G. European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium «Genetics-Driven Targeted Management of Lymphoid Malignancies». Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516-532.
  50. Aladily TN, Medeiros LJ, Alayed K, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: a newly recognized entity that needs further refinement of its definition. Leuk Lymphoma. 2012;53(4):749-750.
  51. Piccaluga PP, Ascani S, Fraternali Orcioni G, Piccioli M, Pileri A Jr, Falini B, Pileri S. Anaplastic lymphoma kinase expression as a marker of malignancy: application to a case of anaplastic large cell lymphoma with huge granulomatous reaction. Haematologica. 2000;85:978-981.
  52. Oishi N, Miranda RN, Feldman AL. Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J. 2019; 39(suppl 1):14-20.
  53. Kadin ME, Adams WP Jr, Inghirami G, Di Napoli A. Does Breast Implant Associated ALCL begin as a Lymphoproliferative Disorder? Plast Reconstr Surg. 2019.
  54. Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(suppl 1):3-13.
  55. Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, Lofts J, Amin MB, Ming Chai S, Morine A, Di Napoli A, Dogan A, Parkash V, Bhagat G, Tritz D, Quesada AE, Pina-Oviedo S, Hu Q, Garcia-Gomez FJ, Jose Borrero J, Horna P, Thakral B, Narbaitz M, Hughes RC 3rd, Yang LJ, Fromm JR, Wu D, Zhang D, Sohani AR, Hunt J, Vadlamani IU, Morgan EA, Ferry JA, Szigeti R, C Tardio J, Granados R, Dertinger S, Offner FA, Pircher A, Hosry J, Young KH, Miranda RN. Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. Am J Surg Pathol. 2018;42(3):293-305.
  56. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W. Breast-implant associated anaplastic large cell lymphoma: sensitivity, specifitiy, and findings of imaging studies in 44 patients. Breast Cancer Res Treat. 2014;147:1-14.
  57. Mehta-Shah N, Clemens MW, Horwitz SM. How I treat breast implant-associated anaplastic large cell lymphoma. Blood. 2018;132(18):1889-1898.
  58. Quesada AE, Medeiros LJ, Clemens MW, Ferrufino-Schmidt MC, Pina-Oviedo S, Miranda RN. Breast implant- associated anaplastic large cell lymphoma: a review. Mod Pathol. 2019;32(2):166-188.
  59. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
  60. Johnson L, O’Donoghue JM, McLean N, Turton P, Khan AA, Turner SD, Lennard A, Collis N, Butterworth M, Gui G, Bristol J, Hurren J, Smith S, Grover K, Spyrou G, Krupa K, Azmy IA, Young IE, Staiano JJ, Khalil H, MacNeill FA. Breast implant associated anaplastic large cell lymphoma: the UK experience Recommendations on its management and implications for informed consent. Eur J Surg Oncol. 2017;43:1393-1401.
  61. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015;33(32):3759-3765.
  62. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vetodin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190-2196.
  63. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positivelymphomas. N Engl J Med. 2010;363(19):1812-1821.
  64. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. ALCANZA study group.Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-celllymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555-566.
  65. Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, Rozati S, Nagpal S, Krathen M, Reddy S, Hoppe RT, Nguyen-Lin A, Weng WK, Armstrong R, Pulitzer M, Advani RH, Horwitz SM. Phase II Investigator-Initiated Study of BrentuximabVedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 ExpressionLevel: A Multi-Institution Collaborative Project. J Clin Oncol. 2015;33(32):3750-3758.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.